scispace - formally typeset
C

Cheng Wang

Researcher at Nanjing Medical University

Publications -  245
Citations -  9359

Cheng Wang is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Lung cancer & Genome-wide association study. The author has an hindex of 42, co-authored 195 publications receiving 7313 citations. Previous affiliations of Cheng Wang include Tianjin Medical University Cancer Institute and Hospital & Tianjin Medical University.

Papers
More filters
Journal ArticleDOI

Associations Between Sleep Quality and Health Span: A Prospective Cohort Study Based on 328,850 UK Biobank Participants.

TL;DR: In this paper, the authors examined the associations between sleep quality and health span using a prospective cohort design based on the UK Biobank (UKB) and found that healthy sleep quality was associated with a reduced risk of premature end of health span, suggesting healthy sleep behavior may extend health span.
Journal ArticleDOI

Genomic Signature of Mismatch Repair Deficiency in Areca Nut-Related Oral Cancer.

TL;DR: This study first revealed the molecular profiles and highlighted the role of dMMR in AN-related OSCC among the Chinese population and identified that AN- related OSCC may represent a potential cohort for effective anti-PD-1/L1 immunotherapy.
Journal ArticleDOI

Genetic Variants at 10p11 Confer Risk of Tetralogy of Fallot in Chinese of Nanjing

TL;DR: The results suggested that the genetic variants on 10p11 may serve as candidate markers for Tetralogy of Fallot susceptibility in Chinese population.
Journal ArticleDOI

A cis-eQTL genetic variant of the cancer–testis gene CCDC116 is associated with risk of multiple cancers

TL;DR: It is suggested that low abundance expression of CT genes in normal tissues may also contribute to tumorigenesis, providing a new mechanism ofCT genes in the development of cancer.
Journal ArticleDOI

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency.

TL;DR: MEIOB played an oncogenic role in TNBC through its involvement in HRD and dysregulation of MEIOB sensitized TNBC cells to PARP inhibitors, so MEioB may be a therapeutic target of PARP1 inhibitors in T NBC.